These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 18852123

  • 1. Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function.
    Basak S, Pookot D, Noonan EJ, Dahiya R.
    Mol Cancer Ther; 2008 Oct; 7(10):3195-202. PubMed ID: 18852123
    [Abstract] [Full Text] [Related]

  • 2. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer.
    Ai J, Wang Y, Dar JA, Liu J, Liu L, Nelson JB, Wang Z.
    Mol Endocrinol; 2009 Dec; 23(12):1963-72. PubMed ID: 19855091
    [Abstract] [Full Text] [Related]

  • 3. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6.
    Gibbs A, Schwartzman J, Deng V, Alumkal J.
    Proc Natl Acad Sci U S A; 2009 Sep 29; 106(39):16663-8. PubMed ID: 19805354
    [Abstract] [Full Text] [Related]

  • 4. PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.
    Gravina GL, Marampon F, Muzi P, Mancini A, Piccolella M, Negri-Cesi P, Motta M, Lenzi A, Di Cesare E, Tombolini V, Jannini EA, Festuccia C.
    Endocr Relat Cancer; 2013 Jun 29; 20(3):321-37. PubMed ID: 23507703
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
    Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K.
    J Biol Chem; 2005 Jul 22; 280(29):26729-34. PubMed ID: 15937340
    [Abstract] [Full Text] [Related]

  • 6. Downregulation of androgen receptors by NaAsO2 via inhibition of AKT-NF-κB and HSP90 in castration resistant prostate cancer.
    Kim Y, Park SE, Moon JW, Kim BM, Kim HG, Jeong IG, Yoo S, Ahn JB, You D, Pak JH, Kim S, Hwang JJ, Kim CS.
    Prostate; 2017 Jul 22; 77(10):1128-1136. PubMed ID: 28556958
    [Abstract] [Full Text] [Related]

  • 7. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor.
    Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP.
    Mol Cell; 2005 May 27; 18(5):601-7. PubMed ID: 15916966
    [Abstract] [Full Text] [Related]

  • 8. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth.
    Cha TL, Qiu L, Chen CT, Wen Y, Hung MC.
    Cancer Res; 2005 Mar 15; 65(6):2287-95. PubMed ID: 15781642
    [Abstract] [Full Text] [Related]

  • 9. FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells.
    Ni L, Yang CS, Gioeli D, Frierson H, Toft DO, Paschal BM.
    Mol Cell Biol; 2010 Mar 15; 30(5):1243-53. PubMed ID: 20048054
    [Abstract] [Full Text] [Related]

  • 10. NBM-T-BBX-OS01, Semisynthesized from Osthole, Induced G1 Growth Arrest through HDAC6 Inhibition in Lung Cancer Cells.
    Pai JT, Hsu CY, Hua KT, Yu SY, Huang CY, Chen CN, Liao CH, Weng MS.
    Molecules; 2015 May 04; 20(5):8000-19. PubMed ID: 25946558
    [Abstract] [Full Text] [Related]

  • 11. Drugging the HDAC6-HSP90 interplay in malignant cells.
    Krämer OH, Mahboobi S, Sellmer A.
    Trends Pharmacol Sci; 2014 Oct 04; 35(10):501-9. PubMed ID: 25234862
    [Abstract] [Full Text] [Related]

  • 12. Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor beta.
    Bektic J, Berger AP, Pfeil K, Dobler G, Bartsch G, Klocker H.
    Eur Urol; 2004 Feb 04; 45(2):245-51; discussion 251. PubMed ID: 14734014
    [Abstract] [Full Text] [Related]

  • 13. Histone Deacetylase 6-Controlled Hsp90 Acetylation Significantly Alters Mineralocorticoid Receptor Subcellular Dynamics But Not its Transcriptional Activity.
    Jiménez-Canino R, Lorenzo-Díaz F, Jaisser F, Farman N, Giraldez T, Alvarez de la Rosa D.
    Endocrinology; 2016 Jun 04; 157(6):2515-32. PubMed ID: 27100623
    [Abstract] [Full Text] [Related]

  • 14. Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90.
    Meng Q, Chen X, Sun L, Zhao C, Sui G, Cai L.
    Mol Cell Biochem; 2011 Feb 04; 348(1-2):165-71. PubMed ID: 21082217
    [Abstract] [Full Text] [Related]

  • 15. Effect of geldanamycin on androgen receptor function and stability.
    Vanaja DK, Mitchell SH, Toft DO, Young CY.
    Cell Stress Chaperones; 2002 Jan 04; 7(1):55-64. PubMed ID: 11894840
    [Abstract] [Full Text] [Related]

  • 16. Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
    Jadhavar PS, Ramachandran SA, Riquelme E, Gupta A, Quinn KP, Shivakumar D, Ray S, Zende D, Nayak AK, Miglani SK, Sathe BD, Raja M, Farias O, Alfaro I, Belmar S, Guerrero J, Bernales S, Chakravarty S, Hung DT, Lindquist JN, Rai R.
    Bioorg Med Chem Lett; 2016 Nov 01; 26(21):5222-5228. PubMed ID: 27717544
    [Abstract] [Full Text] [Related]

  • 17. Arsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6.
    Qu X, Du J, Zhang C, Fu W, Xi H, Zou J, Hou J.
    PLoS One; 2012 Nov 01; 7(2):e32215. PubMed ID: 22384180
    [Abstract] [Full Text] [Related]

  • 18. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
    Solit DB, Zheng FF, Drobnjak M, Münster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N.
    Clin Cancer Res; 2002 May 01; 8(5):986-93. PubMed ID: 12006510
    [Abstract] [Full Text] [Related]

  • 19. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells.
    Bhattacharyya RS, Krishnan AV, Swami S, Feldman D.
    Mol Cancer Ther; 2006 Jun 01; 5(6):1539-49. PubMed ID: 16818513
    [Abstract] [Full Text] [Related]

  • 20. Beyond androgen deprivation: ancillary integrative strategies for targeting the androgen receptor addiction of prostate cancer.
    McCarty MF, Hejazi J, Rastmanesh R.
    Integr Cancer Ther; 2014 Sep 01; 13(5):386-95. PubMed ID: 24867960
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.